Company: GEHC
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001932393-25-000053
Chunk: 131

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 2
Chunk 131
---
,4872,4083%Total revenues    $5,143$4,8636%$14,927$14,3534%

For the three months ended September 30, 2025

Total revenues were $5,143 million, growing 6% as reported and 4% organically*. Sales of products increased 5% or $174 million primarily driven by strong growth in PDx, Imaging, and AVS revenues. Sales of services increased 6% or $107 million primarily driven by growth in new and existing customer contractual agreements.

____________________

*Non-GAAP Financial Measure

33

The segment revenues were as follows:

•Imaging segment revenues were $2,349 million, growing 5% or $120 million, led by growth in the EMEA and USCAN regions;

•AVS segment revenues were $1,301 million, growing 7% or $84 million, with strength in the U.S. market;

•PCS segment revenues were $731 million, decreasing 6% or $48 million, primarily driven by a product hold; and

•PDx segment revenues were $749 million, growing 20% or $124 million as reported, driven by the acquisition of Nihon Medi-Physics Co., Ltd. (“NMP”) and an increase in Organic revenue*. Organic revenue* grew 10% driven by continued growth in volume and price.

The regional revenues were as follows:

•USCAN revenues were $2,358 million, growing 5% or $112 million with growth across AVS, PDx, and Imaging segment revenues, partially offset by a decline in PCS revenues;

•EMEA revenues were $1,360 million, growing 10% or $123 million, with growth in Imaging, AVS, and PDx revenues, as well as favorable foreign currency impacts;

•China region revenues were $547 million, decreasing 3% or $17 million due to a decrease in AVS and PCS revenues, partially offset by growth in PDx revenues; and

•Rest of World revenues were $879 million, growing 8% or $63 million due to growth in PDx revenues, inclusive of NMP revenues, and Imaging revenues.

For the nine months ended September 30, 2025

Total revenues were $14,927 million, growing 4% as reported and 3% organically*. Sales of products increased 3% or $301 million primarily driven by strong growth in PDx, AVS, and